Adagene Inc-adr (ADAG)
$2.75
+0.1
(+3.77%)▲
Insights on Adagene Inc-adr
Increasing Revenue
Revenue is up for the last 2 quarters, 407.87K → 833.33K (in $), with an average increase of 51.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, -2.05M → -15.15M (in $), with an average decrease of 95.0% per quarter
Performance
- $2.75$2.75$2.75
0.0%
Downside
Day's Volatility :0.0%
Upside
0.0%
- $1.10$4.38$2.75
60.0%
Downside
52 Weeks Volatility :74.89%
Upside
37.21%
Returns
| Period | Adagene Inc-adr | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -36.14% | 2.0% | 0.0% |
6 Months | 93.43% | 11.7% | 0.0% |
1 Year | 103.85% | 5.8% | 1.3% |
3 Years | -81.31% | 14.2% | -22.1% |
Highlights
Market Capitalization | 120.5M |
Book Value | $1.6 |
Earnings Per Share (EPS) | -0.44 |
Wall Street Target Price | 12.0 |
Profit Margin | -104.61% |
Operating Margin TTM | -2288.81% |
Return On Assets TTM | -11.06% |
Return On Equity TTM | -24.66% |
Revenue TTM | 18.1M |
Revenue Per Share TTM | 0.41 |
Quarterly Revenue Growth YOY | -84.8% |
Gross Profit TTM | 10.2M |
EBITDA | -22.7M |
Diluted Eps TTM | -0.44 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.66 |
EPS Estimate Next Year | -0.9 |
EPS Estimate Current Quarter | -0.42 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 336.36%
Technicals Summary
Sell
Neutral
Buy
Adagene Inc-adr is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Adagene Inc-adr | 3.52% | 93.43% | 103.85% | -81.31% | -81.31% |
 Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
 Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
 Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
 Vertex Pharmaceuticals Incorporated | -2.67% | 9.62% | 21.65% | 86.62% | 134.62% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Adagene Inc-adr | NA | NA | NA | -1.66 | -0.25 | -0.11 | NA | 1.6 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Adagene Inc-adr | Buy | $120.5M | -81.31% | NA | -104.61% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 134.62% | 28.81 | 36.68% |
Institutional Holdings
Wuxi AppTec Co Ltd
9.58%SC China Holding Ltd
3.05%Artal Group S A
2.27%General Atlantic Llc
0.60%Morgan Stanley - Brokerage Accounts
0.33%FMR Inc
0.28%
Corporate Announcements
Adagene Inc-adr Earnings
Adagene Inc-adr’s price-to-earnings ratio stands at None
Read More
Company Information
adagene was co-founded by two serial entrepreneurs to power antibody discovery. its aim is to become the leading player in antibody discovery and engineering. it has developed a proprietary dynamic precision library (dpl) and is showcasing the power of the library with a unique pipeline of innovative antibody therapeutics that is advancing into clinical trials. adagene previously has raised three series of financing with over $86 million. investors include f-prime capital (formerly fidelity biosciences), eight roads ventures china (formerly fidelity growth partners asia), 6 dimensions capital, gp healthcare capital, sequoia china, and new world tmt. for more information, please visit www.adagene.com.
Organization | Adagene Inc-adr |
Employees | 174 |
CEO | Dr. Peter P. Luo Ph.D. |
Industry | Healthcare |
